In a recent study, researchers looked to determine whether a symptom and psychosocial collaborative care intervention would improve heart failure–specific health status, depression, and symptom burden in patients with heart failure.
In a study recently published in JAMA Internal Medicine, researchers sought determine whether a symptom and psychosocial collaborative care intervention would improve heart failure—specific health status, depression, and symptom burden in patients with heart failure.
Researchers created a single-blind, double-arm, multisite randomized trial that was conducted at Department of Veterans Affairs, academic, and safety-net health systems in Colorado among outpatients with symptomatic heart failure and reduced health status. Patients were recruited and enrolled in the trial between August 2012 and April 2015.
Within the trial, patients were randomized 1:1 to receive the Collaborative Care to Alleviate Symptoms and Adjust to Illness (CASA) intervention or usual care. The CASA intervention meant that collaborative symptom care was provided by a nurse, and psychosocial care was provided by a social worker, both of whom worked with the patients’ primary care physicians.
Of the 314 patients randomized (157 to the intervention arm and 157 to the control arm), 67 were women and 247 were men. The mean age of participants was 65.5 years, and 178 (56.7%) had reduced ejection fraction. The primary outcome of the study was patient-reported heart failure—specific health status, as measured by a difference in change scores on the Kansas City Cardiomyopathy Questionnaire (range 0-100) at 6 months.
Secondary outcomes included:
At 6 months, the mean Kansas City Cardiomyopathy Questionnaire score improved 5.5 points in the intervention arm, and 2.9 points in the control arm (2.6; 95% CI, —1.3 to 6.6; P = .19). In terms of secondary outcomes, depressive symptoms and fatigue improved at 6 months in the intervention arm, effect size of —.29 (95% CI: –.53 to –.004, P = .02) for depressive symptoms and —.30 (95% CI, -.55 to –.006, P = .02) for fatigue, respectively.
Overall, however, the researchers found that the CASA intervention did not significantly demonstrate improved heart failure—specific health status. Conversely, secondary outcomes of depression and fatigue did improve.
Reference
Bekelman D, Allen L, McBryde C, et al. Effect of a collaborative care intervention vs usual care on health status of patients with chronic heart failure. JAMA Intern Med. 2018;178(4):511-519. doi:10.1001/jamainternmed.2017.8667
What It Takes to Improve Guideline-Based Heart Failure Care With Ty J. Gluckman, MD
August 5th 2025Explore innovative strategies to enhance heart failure treatment through guideline-directed medical therapy, remote monitoring, and artificial intelligence–driven solutions for better patient outcomes.
Listen
Genetics, Comorbidities Associated With Cardiomyopathy and Atrial Fibrillation
August 13th 2025The cause of dilated cardiomyopathy (DCM) can be associated with the presence of the TTN gene combined with preexisting comorbidities like atrial fibrillation, which increase the odds of developing DCM.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Strategies Needed to Address Physical Activity Before, After CVD Events
August 1st 2025Black women had lower moderate-to-vigorous intensity physical activity scores when compared with Black and White men and their White female counterparts, highlighting the need for support across patient subgroups.
Read More
AI-Enhanced ECG Expands Access, Reduces Costs for Patients
July 25th 2025An AI model significantly outperformed cardiologists when reviewing ECGs of structural heart disease and may potentially be a step towards increased access and lower costs for early detection of conditions like heart failure and valvular heart disease.
Read More